18/09/2019 24 Should NICE consider a broader societal perspective when assessing new gene therapies? By Lily Sanders | Health Economics | No Comments Dan Howard and Hannah Gillies from our Health Economics team explore some of the themes from a recent Health Affairs Blog article on the implications of new cell and gene therapies on HTA: ‘Putting The Costs And...Read More
